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Abstract
Purpose The diagnosis of behavioural variant frontotemporal
dementia (bvFTD) is challenging during the predementia
stage when symptoms are subtle and confounding.
Morphological and functional neuroimaging can be particu-
larly helpful during this stage but few data are available.
Methods We retrospectively selected 25 patients with late-
onset probable bvFTD. Brain structural MRI and FDG PET
were performed during the predementia stage (mean MMSE
score 27.1±2.5) on average 2 years before. The findings with
the two imaging modalities were compared (SPM8) with
those in a group of 20 healthy subjects. The bvFTD patients
were divided into two subgroups: those with predominant
disinhibition (bvFTD+) and those with apathy (bvFTD−).
Results Hypometabolism exceeded grey matter (GM) density
reduction in terms of both extension and statistical signifi-
cance in all comparisons. In the whole bvFTD group,
hypometabolism involved the bilateral medial, inferior and
superior lateral frontal cortex, anterior cingulate, left temporal
and right parietal cortices and the caudate nuclei. GM density
reduction was limited to the right frontal cortex and the left
medial temporal lobe. In bvFTD+ patients hypometabolism
was found in the bilateral medial and basal frontal cortex,
while GM reduction involved the left anterior cingulate and
left inferior frontal cortices, and the right insula. In bvFTD−
patients, atrophy and mainly hypometabolism involved the
lateral frontal cortex and the inferior parietal lobule.
Conclusion These findings suggest that hypometabolism is
more extensive than, and thus probably precedes, atrophy in
predementia late-onset bvFTD, underscoring different topo-
graphic involvement in disinhibited and apathetic presenta-
tions. If confirmed in a larger series, these results should
prompt biomarker operationalization in bvFTD, especially
for patient selection in therapeutic clinical trials.
Keywords Frontotemporal dementia . Brain PET .Mild
cognitive impairment
Introduction
The most frequent subtype of frontotemporal dementia (FTD)
is the behavioural variant (bvFTD), that is characterized by
progressive deterioration in personality, social behaviour and
cognition. Although genetic causes are increasingly recog-
nized [1], the majority of cases are still sporadic [2].
Diagnostic criteria include ‘possible’ FTD when at least three
of six behavioural or cognitive hallmarks are found without
significant impact on functional autonomy [3]. This stage
would theoretically correspond to the mild cognitive impair-
ment (MCI) construct of Alzheimer’s disease (AD) [4] and
often behavioural symptoms dominate in cognitive
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impairment, ‘early apathy’ and ‘early disinhibition’ being
largely the most frequent presentations [3, 5, 6]. To delineate
this stage, the concept of mild behavioural impairment has
been proposed [7]. Interestingly, changes in morphological
and/or functional neuroimaging are included in the criteria
for probable FTD but not in those for possible FTD [3]. Yet
neuroimaging changes would be even more relevant during
the predementia stage, as in AD where neuroimaging bio-
markers increase the likelihood of diagnosis during the MCI
stage [8]. It has been shown that both atrophy [9, 10] and
hypometabolism/hypoperfusion [6, 11–17] are detectable ear-
ly in anterior cortical regions in overt FTD, when they can
support the diagnosis [18] and help differentiate bvFTD from
psychiatric disorders in the elderly [19]. In principle,
hypometabolism/hypoperfusion, that are exquisitely sensitive
to synaptic dysfunction [20], should be detectable earlier and
be more extensive than atrophy [15, 16, 21]
The a im of th is s tudy was to ver i fy whether
hypometabolism is more extensive than, and thus probably
precedes, atrophy in patients with probable bvFTD investigat-
ed during the predementia stage.
Methods
Patients
Outpatients examined during the period 2011 – 2013 were
selected retrospectively from the clinical database of the
Dementia Center of the University Hospital, with the follow-
ing characteristics: (1) evaluated for the first time and with a
diagnosis of possible bvFTD, thus without dementia [3], (2)
underwent both MRI, including volumetric T1-weighted se-
quences, and 18F-FDG PET at baseline during the first diag-
nostic work-up, and (3) clinically followed until they devel-
oped probable bvFTD [3]. These constraints resulted in the
selection of a group of patients with probable bvFTD investi-
gated during the predementia stage. Specifically the
predementia state was defined (1) according to the clinical
diagnostic criteria for ‘possible’ FTD thus involving at least
three of six behavioural or cognitive hallmarks but without a
significant impact on functional autonomy, (2) by a score of
0.5 on the standardized Clinical Dementia Rating (CDR) ad-
ministered according to the standard method [22], and (3) by
the lack of a substantial impact of disturbances on everyday
living and autonomy (thus matching the concept of MCI)
shown by both an unstructured clinical interview with infor-
mants and administration of the structured Activities of Daily
Living (ADL) and Instrumental ADL (IADL) scales. The
main exclusion criteria were a psychiatric diagnosis according
to the DSM-IVr criteria, any somatic, metabolic or other neu-
rological disease potentially accounting for the cognitive or
behavioural disturbances. On MRI, brain infarcts and severe
white matter disease (i.e. a score of 3 in any region on the Age-
RelatedWhite Matter Changes scale [23]) were also exclusion
criteria.
These criteria identified 25 patients for inclusion. None of
the patients had signs or symptoms of motor neuron disease.
The family history was positive for dementia or major psychi-
atric illnesses in at least one first-degree relative in ten and two
patients, respectively. Genetic status with respect to C9orf72,
TARDBP and PGRN mutations was available in all patients,
and was negative. At the first evaluation, all patients
underwent a battery of neuropsychological tests evaluating
verbal learning and delayed recall, working memory, atten-
tion, cognitive flexibility, language, abstraction, and visuospa-
tial abilities. Each patient’s behavioural profile was assessed
by means of the Neuropsychiatric Inventory (NPI). The neu-
ropsychological test scores were corrected for age and educa-
tion according to published normative data in the local lan-
guage. The main demographic and clinical characteristics of
the patients are presented in Table 1 and the mean neuropsy-
chological test scores in Table 2.
Patients were then divided into two subgroups according to
the prevalence of positive or negative symptoms, established
on the basis of clinical examination and unstructured inter-
views with the patients and their caregivers (Table 3). Then
the total NPI score and item subscores were compared be-
tween the two subgroups (t test) and significant differences
were found for agitation, euphoria, disinhibition, irritability
(significantly higher in the subgroup with positive symptoms,
bvFTD+), depression and apathy (significantly more severe in
the group with negative symptoms, bvFTD−; Table 4).
Patients underwent clinical and neuropsychological
follow-up until they developed signs and symptoms matching
the diagnostic criteria for probable FTD, which occurred 6 to
43 months later (mean 22.7 ± 12.2 months) with a mean
MMSE score of 23.5±6.6. Dementia was established by clin-
ical interviews with patients and caregivers using the struc-
tured CDR scale as well as the ADL and IADL questionnaires
According to the current diagnostic criteria [3], significant
atrophy and/or hypometabolism in frontotemporal regions is
Table 1 Demographic and clinical characteristics of the patients with
predementia bvFTD and healthy controls
Characteristic bvFTD Controls p valuea
No. of subjects 25 20
Age (years), mean ± SD 71.7 ± 6.8 69.1 ± 7.8 Not significant
Gender (m/f), n 13/12 9/11 Not significant
Education (years), mean ± SD 11.0 ± 7.9 10.9 ± 3.8 Not significant
Mini-mental state examination score, mean ± SD
Predementia stage 27.1 ± 2.5 29.5 ± 1.0 <0.001
Dementia stage 23.5 ± 6.6 –
a Unpaired t test
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needed to formulate the diagnosis of probable FTD. MRI and
FDG PET images were qualitatively evaluated by a neurolo-
gist with expertise in neuroimaging (F.N.) and by a nuclear
medicine physician with expertise in nuclear neurology
(S.M.), respectively. Significant atrophy was detected in 15
patients (60 %), whereas significant hypometabolism was
found in all patients.
Control subjects
Control subjects were healthy volunteers who gave their
informed consent and had participated in a previous study
[24]. Their healthy status was carefully checked by means
of general medical history and clinical examination.
Control subjects were submitted to the same exclusion
criteria as the patients and underwent both MRI with T1-
weighted volumetric sequences and FDG PET. Only sub-
jects with a CDR score of 0 and a normal MMSE score (i.e.
>26) were included. Control subjects underwent the same
neuropsychological test battery as the patients, and only
subjects with normal scores (Z score >−1.5) in all tests were
further considered. The healthy status of all 20 subjects was
confirmed by clinical interview 1 year later. Demographic
and neuropsychological characteristics are presented in
Tables 1 and 2, respectively.
The study protocol was approved by the local Ethics
Committee and an informed consent was signed by all partic-
ipants, in compliance with the Declaration of Helsinki.
18F-FDG PET protocol and preprocessing
FDG PET was performed according to the guidelines of the
European Association of Nuclear Medicine [25]. Briefly, sub-
jects fasted for at least 6 h. Before radiopharmaceutical injec-
tion, blood glucose was checked and was <7.8 mmol/l in all
subjects. After 10 min rest in a quiet and darkened room, with
their eyes closed and no ear plugs, subjects were injected with
approximately 200 MBq of 18F-FDG via a venous cannula.
They remained in the room for 30 min after the injection and
then moved to the PET room where scanning was started
approximately 45 min after the injection. A polycarbonate
head holder was used to reduce head movement during the
scan. Images were acquired using a Siemens Biograph 16
PET/CT system with a total axial field of view of 15 cm and
no interplane gap. The scan acquisition time was 15 min in
three-dimensional mode. Images were reconstructed using an
ordered subsets expectation maximization algorithm (16 sub-
sets and six iterations) with a reconstructed voxel size of
1.33×1.33×2.00 mm. Attenuation correction was based on
the CT scan. DICOM files were exported and converted into
Analyse files.
FDG PET images were subjected to affine and nonlinear
spatial normalization into the Talairach and Tournoux space
using SPM8 (Wellcome Department of Cognitive Neurology,
London, UK) implemented in MATLAB 7.5 (MathWorks,
Natick, MA). The spatially normalized set of images was then
smoothed with a 10-mm isotropic gaussian filter to blur indi-
vidual variations in gyral anatomy and to increase the signal-
to-noise ratio. All the default choices of SPM8 were followed
with one exception. Since it has been shown that the use of the
tracer unmatched PET template to normalize brain scans may
generate inconsistent results [24] and because the default SPM
brain PET template is an H2
15O template, a customized brain
FDG PET template was used [24].
Table 2 Neuropsychological test scores in patients with predementia
bvFTD and healthy controls
Test bvFTD Controls p valuea
Verbal fluency
Categorical 26.4 ± 12.5 39.8 ± 10.9 <0.001
Phonological 22.3 ± 14.1 38.3 ± 10.4 <0.001
Stroop test
Colour 29.6 ± 7.9 44.5 ± 7.8 <0.0001
Colour–word 8.3 ± 6.4 20.4 ± 7.0 <0.0001
Digit span 5.2 ± 1.0 5.8 ± 0.9 <0.05
Trailmaking test
A 82.3 ± 43.9 46.4 ± 17.3 <0.001
B 377.6 ± 213.4 97.9 ± 43.9 <0.0001
Digit symbol 22.7 ± 12.4 39.3 ± 8.3 <0.0001
Rey auditory verbal learning
Immediate recall 28.2 ± 11.6 41.4 ± 7.9 <0.0001
Delayed recall 3.8 ± 3.7 8.5 ± 2.6 <0.0001
Constructional praxis
Simple copy 8.4 ± 1.5 9.4 ± 1.0 <0.05
Copy with landmarks 62.8 ± 6.1 67.0 ± 2.0 <0.01
Clock drawing 1.7 ± 2.5 0.6 ± 1.7 Not significant
Corsi block design 4.0 ± 1.2 4.5 ± 0.6 Not significant
Values are means ± standard deviation
a Unpaired t test
Table 3 Demographic characteristics of the two bvFTD subgroups
Characteristic bvFTD+a bvFTD−b p valuec
No. of subjects 12 13
Age (years), mean ± SD 71.9 ± 7.8 71.6 ± 5.8 Not significant
Gender (m/f), n 8/4 5/8 Not significant
Education (years), mean ± SD 10.0 ± 6.3 12.0 ± 8.9 Not significant
MMSE score, mean ± SD 27.7 ± 3.5 26.6 ± 1.5 Not significant
a bvFTD subgroup with prevalence of positive symptoms
b bvFTD subgroup with prevalence of negative symptoms
cUnpaired t test
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MRI protocol and preprocessing
MRI volumes were obtained using a 1.5-T scanner (Signa
Excite; GE Healthcare, Milwaukee, WI) with an eight-coil
transmit–receive head coil acquiring volumetric T1 imag-
ing using a coronal T1-weighted 3D spoiled gradient
recalled (SPGR) sequence (TR/TE 10.0 ms/4.5 ms, flip
angle 8°, field of view 24 × 24 cm, matrix 256 × 256).
MRI images were obtained within 2 months of the PET
examination. Images were preprocessed with SPM, using
a modified optimized voxel-based morphometric technique
[26]. First, a customized sample-specific whole-brain tem-
plate was computed, and an a priori map for grey matter
(GM), white matter and cerebrospinal fluid were deter-
mined by segmenting the sample-specific whole-brain tem-
plate into the three components based on image intensity
classification and probability of tissue class membership.
Each individual MR scan was normalized to the whole-
brain sample-specific template and then segmented into
GM, white matter and cerebrospinal fluid components
using information from the sample-specific tissue classifi-
cation templates. The individual GM images were further
spatially normalized to the sample-specific GM using a 12-
parameter affine transformation and nonlinear adjustments
with 7 × 8 × 7 basis functions. The segmented, normalized
images were finally smoothed with an 8-mm full-width at
half-maximum gaussian kernel to compensate for interin-
dividual variability and conform the data to a gaussian dis-
tribution to enable the use of the random field theory which
provides corrected statistical inference.
Statistics
FDG PET and segmented GM maps were compared between
the control group and the whole group of bvFTD patients.
Then, to fully explore GM density reduction and
hypometabolic patterns related to different behavioural pro-
files, FDG PET and GM images from the bvFTD+ and
bvFTD− subgroups were independently compared with those
from the control group. All comparisons were performed on a
voxel-by-voxel basis using the SPM8 two-sample t-test op-
tion, with age and education as nuisance variables. All SPM T
maps were displayed using an uncorrected p<0.001 at peak
level. Clusters of differences were regarded as significant if
they survived at a threshold of p<0.05, corrected for family-
wise error at the cluster level. Only significant clusters con-
taining at least 100 (FDG PET) or 50 (GM density) voxels
were taken into consideration. The p<0.001 height threshold
at the voxel level was adopted to avoid type II errors attribut-
able to over-conservative thresholds [27]. In fact, given the
exploratory nature of the study and especially considering
the relatively low sensitivity of PET and MRI without repeat-
ed measures, higher thresholds could have led to false-
negative results.
The SPM coordinates were corrected to match the
Talairach coordinates using BrainMap GingerALE 2.3
[28]. Brodmann areas (BA) were then identified at a
range of 0 to 3 mm from the corrected Talairach coor-
dinates of the SPM output isocentres, after importing
the corrected coordinates by means of Talairach Client
(http://www.talairach.org/index.html).
Table 4 Neuropsychiatric
Inventory subscores of the two
bvFTD subgroups
Item bvFTD+a bvFTD−b p valuec
Delusions 1.8 ± 0.5 1.2 ± 0.5 Not significant
Hallucinations 0.3 ± 0.1 0 Not significant
Agitation 2.5 ± 1.6 0.5 ± 1.1 <0.05
Depression 1.0 ± 1.9 4.3 ± 4.1 <0.01
Anxiety 2.1 ± 1.6 2.1 ± 3.0 Not significant
Euphoria 2.0 ± 1.1 0 <0.05
Apathy 1.7 ± 2.5 3.8 ± 2.8 <0.05
Disinhibition 3.6 ± 3.9 0.4 ± 1.6 <0.01
Irritability 4.0 ± 3.9 0.7 ± 1.4 <0.01
Aberrant motor behaviour 1.5 ± 3.7 2.4 ± 3.1 Not significant
Nocturnal behaviour disorder 1.1 ± 2.1 1.0 ± 2.0 Not significant
Appetite and eating abnormalities 2.7 ± 1.8 2.5 ± 4.3 Not significant
Total score 24.0 ± 17.1 18.9 ± 12.4 Not significant
Values are means ± standard deviation
a bvFTD subgroup with prevalence of positive symptoms
b bvFTD subgroup with prevalence of negative symptoms
cUnpaired t test
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Results
Comparisons between the control and bvFTD group
The bvFTD group showed lower GM density in the right
inferior frontal gyrus (BA9-44) as well as in the thalamus,
claustrum and parahippocampal gyrus in the left hemisphere
(Fig. 1a, Table 5). Hypometabolism was found in a larger
cluster in both hemispheres involving the superior (bilateral
BA10 and right BA9), medial (BA10) and inferior (right
BA13, left BA45) frontal gyri, the anterior cingulate gyrus
(bilateral BA32 and right BA24) and the caudate nucleus,
and in the left hemisphere involving the middle frontal gyrus
(BA46) and the superior temporal gyrus (BA22). A smaller
cluster was present in the right inferior parietal lobule (BA40;
Fig. 1b, Table 6).
Comparisons between the control group and bvFTD+
subgroup
In the bvFTD+ subgroup a reduction in GM density was
found in two small clusters involving the inferior frontal gyrus
(BA9-44) and cingulate gyrus (BA31) in the left hemisphere,
and the insula and claustrum in the right hemisphere (Fig. 2a,
Table 5). However, hypometabolism was highlighted in two
larger clusters involving the medial frontal gyrus (bilateral
BA25 and right BA10) in both hemispheres, the inferior fron-
tal gyrus (BA45), postcentral gyrus (BA40-43) and caudate
nucleus in the left hemisphere, and the superior temporal gy-
rus (BA38) and insula in the right hemisphere (Fig. 2b,
Table 6).
Comparisons between the control group and bvFTD−
subgroup
In the bvFTD− subgroup GM density reduction was found in
the left superior (BA10) and right inferior (BA9) frontal gyri,
and the left precentral gyrus (BA44) and left inferior parietal
lobule (BA40; Fig. 2c, Table 5). In contrast, two clusters of
significant hypometabolism were found including the left su-
perior (BA10) and inferior (BA47) frontal gyri, the bilateral
inferior parietal lobule (BA40) and the right precentral gyrus
(BA44) (Fig. 2d, Table 6).
Discussion
In this multi-modal imaging study we demonstrated signifi-
cant GM atrophy and hypometabolism in a group of patients
with late-onset bvFTD in the predementia stage. In particular,
cortical and subcortical hypometabolism was significantly
more extensive than GM atrophy, suggesting that functional
network damage occurs earlier than anatomical damage.
Disinhibited or apathetic presentations were shown to be as-
sociated with different functional patterns even in the early
stage of bvFTD. This retrospective study was indeed designed
Fig. 1 Comparison between healthy controls and the whole group of
bvFTD patients in the predementia stage. Clusters with significant grey
matter density reduction are shown superimposed on a MRI template (a)
while clusters with significant glucose hypometabolism are superimposed
on a PET template (b). In the whole group grey matter density reduction
involves the right inferior frontal gyrus, thalamus, claustrum and
parahippocampal gyrus in the lef t hemisphere (a) while
hypometabolism is seen in the frontal lobes, anterior temporal lobes,
caudate nuclei and thalami of both hemispheres (b). The colour bars
indicate the level of Z scores for significant voxels. Note that the range
of colour bars is 0 – 4 for MRI and 0 – 6 for FDG PET reflecting the
higher level of statistical significance for the latter. See Tables 5 and 6 for
details of Talairach coordinates
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to analyse data from patients matching the highest level of
certainty for the diagnosis of bvFTD in vivo, but studied on
average about 2 years before the diagnosis of dementia, when
they were evaluated for the first time. As in AD, attempts to
characterize the prodromal stage of bvFTD are ongoing and
may help the planning of interventions and the interception of
early disease for clinical trials [16].
Hypometabolism and GM density reduction
in predementia bvFTD patients
The finding that cortical and subcortical hypometabolism is
more extensive than, and thus probably precedes, GM atrophy
is in keeping with a recent study reporting insula, orbitofrontal
and anterior cingulate hypometabolism without atrophy in 9
progranulin mutation carriers and 11 noncarriers without de-
mentia [16]. Of note, a study evaluating FDG PET only in
patients eventually developing bvFTD but without signs of
atrophy showed a specificity of 92 % and a sensitivity of
47 % for FDG PET [7]. In another study a substantial overlap
between hypometabolism and GM density reduction compar-
ing MAPT gene carriers and noncarriers was found, but
comparisons with healthy controls were not carried out [29].
In 14 patients with mild but overt FTD, including all FTD
subtypes, atrophy and hypometabolism showed a greater
overlap than in subjects with subjective cognitive impairment
[15], but again FDG PET was more accurate than structural
MRI in differentiating these 14 patients from controls [30].
Also, in FTD-amyotrophic lateral sclerosis complex a consid-
erable overlap between atrophy and hypometabolism was
found but hypometabolism exceeded atrophy in several re-
gions [31]. These data suggest that changes seen on FDG
PET appear earlier than those seen on structural MRI at the
very beginning of the disease, whilst there is more overlap
between the findings of the two imaging modalities during
the overt dementia stage. This is in accordance with the edi-
torial opinion of Rabinovici and Boeve [32] commenting on
the results of Chiu et al. [14]. In contrast, a negative FDG PET
scan in a patient with suspected early FTD (i.e. possible FTD)
should identify benign phenocopies that eventually do not
convert to overt FTD, as also suggested by other authors
[15, 19, 33].
In our bvFTD group hypometabolism involved not only
the frontotemporal regions and insula, but also the caudate
Table 5 Results of the voxel-based comparisons of grey matter density between the control group and the whole group of bvFTD patients, and
between the control group and the bvFTD+ and bvFTD− subgroups separately
Comparison Significant clusters
Cluster level Peak level
Cluster extent
(no. of voxels)
Corrected
p value
Cortical region Maximum
Z score
Talairach coordinates Region Brodmann
area
Controls vs. bvFTD 435 0.008 Right frontal 4.27 51 9 18 Inferior frontal gyrus 44
Right frontal 4.14 48 15 25 Inferior frontal gyrus 9
433 0.009 Left sublobar 4.42 −6 −25 3 Thalamus Pulvinar
Left temporal 4.16 −30 −39 −3 Hippocampus
Left limbic 4.10 −16 −37 6 Parahippocampal gyrus 30
Left sublobar 4.06 −36 −4 8 Claustrum
Controls vs. bvFTD+ 486 0.007 Left frontal 4.25 −46 9 18 Inferior frontal gyrus 44
Left frontal 4.11 −50 19 29 Inferior frontal gyrus 9
Right sublobar 4.52 42 43 11 Insula 13
284 0.050 Right sublobar 4.33 51 11 16 Claustrum
Left limbic 3.62 46 21 −1 Cingulate gyrus 31
Controls vs. bvFTD− 3,000 0.002 Left frontal 3.69 −36 53 14 Superior frontal gyrus 10
Left frontal 3.25 −51 16 7 Precentral gyrus 44
Left parietal 3.98 −46 −44 43 Inferior parietal lobule 40
Right frontal 3.77 48 15 25 Inferior frontal gyrus 9
Uncorrected p < 0.001 at peak level and p< 0.05, corrected for multiple comparisons with the family-wise error option, at cluster level were accepted as
statistically significant
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Table 6 Results of the voxel-based comparisons of brain metabolism between the control group and the whole group of bvFTD patients, and between
the control group and the bvFTD+ and bvFTD− subgroups separately
Comparison Significant clusters
Cluster level Peak level
Cluster extent
(no. of voxels)
Corrected
p value
Cortical region Maximum
Z score
Talairach
coordinates
Region Brodmann
area
Controls vs.
bvFTD
17,460 0.003 Left frontal 7.41 −36 53 14 Superior frontal gyrus 10
Left sublobar 6.85 −14 12 12 Caudate
Right sublobar 6.71 8 10 12 Caudate
Right frontal 6.63 18 62 −3 Medial frontal gyrus 10
Right sublobar 6.5 6 12 9 Caudate
Left frontal 6.39 −44 42 24 Middle frontal gyrus 46
Left frontal 6.33 −10 55 10 Medial frontal gyrus 10
Right sublobar 6.14 10 9 18 Caudate
Right sublobar 6.13 38 21 −4 Extranuclear 47
Right sublobar 6.08 6 18 6 Caudate
Left frontal 6.04 −51 16 7 Precentral gyrus 44
Left temporal 5.92 −53 10 1 Superior temporal gyrus 22
Left frontal 5.88 −51 27 6 Inferior frontal gyrus 45
Left frontal 5.76 −28 58 1 Superior frontal gyrus 10
Right frontal 5.76 26 58 25 Superior frontal gyrus 10
Right frontal 5.76 28 46 29 Superior frontal gyrus 9
Right frontal 5.72 36 24 8 Inferior frontal gyrus 13
Left sublobar 5.64 −8 4 −4 Caudate
Right limbic 5.56 2 8 36 Cingulate gyrus 24
Left frontal 5.53 −10 10 36 Cingulate gyrus 32
Left limbic 5.52 −14 12 38 Cingulate gyrus 32
Left sublobar 5.51 −6 6 0 Caudate
400 0.01 Right parietal 5.51 50 −47 36 Inferior parietal lobule 40
Controls vs.
bvFTD+
1,725 0.0001 Right frontal 6.63 6 17 −18 Medial frontal gyrus 25
Left sublobar 6.36 −16 9 18 Caudate
Left frontal 5 −12 24 −18 Medial frontal gyrus 25
Right sublobar 4.91 38 22 12 Insula 13
Right sublobar 5.35 36 21 −4 Extranuclear 47
Right sublobar 5.32 34 15 −9 Extranuclear 13
4,822 0.0001 Right temporal 5.19 44 9 −14 Superior temporal gyrus 38
Left frontal 4.52 −42 18 12 Inferior frontal gyrus 45
Right frontal 4.45 16 62 −3 Medial frontal gyrus 10
Left parietal 4.23 −51 −19 18 Postcentral gyrus 43
Left parietal 4.10 −61 −24 21 Postcentral gyrus 40
Controls vs.
bvFTD−
4,535 0.001 Left frontal 5.16 −16 57 21 Superior frontal gyrus 10
Left frontal 4.50 −38 23 −5 Inferior frontal gyrus 47
Left parietal 4.00 −46 −44 43 Inferior parietal lobule 40
Right frontal 3.94 51 16 7 Precentral gyrus 44
221 0.005 Right parietal 4.60 50 −47 36 Inferior parietal lobule 40
Uncorrected p < 0.001 at peak level and p< 0.05, corrected for multiple comparisons with the family-wise error option, at cluster level were accepted as
statistically significant
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nuclei and distant brain regions, functionally connected with
the frontal cortex via the frontoparietal bundles, such as the
inferior parietal lobule. The caudate nucleus is a key part of
the frontostriatal network and contributes to executive dys-
function in FTD, while the finding of parietal hypometabolism
highlights the specific mechanism underlying reduced glucose
uptake, that is, synaptic disconnection from distant (frontal)
regions. Instead, GM atrophy was confined to smaller clusters
in the bilateral medial frontal gyrus, left thalamus and medial
temporal lobe structures. These findings confirm that FDG
PET is more sensitive than MRI morphometry in detecting
cortical damage in the early stages of bvFTD, since changes
specifically targeting synaptic dysfunction and rarefaction
[20] precede atrophy at the same sites as reported for other
neurodegenerative diseases [34]. The relatively low sensitivity
of structural MRI has already been shown in a study in 51
bvFTD patients, about half of whom failed to show significant
atrophy by visual analysis even 5 years on average after diag-
nosis [35].
We also found some areas of overlapping atrophy and
hypometabolism, and some small areas of atrophy without
hypome t abo l i sm . A t rophy wi t hou t s i gn i f i c an t
Fig. 2 Comparison between healthy controls and the bvFTD+ subgroup
(a, b), and the bvFTD− subgroup (c, d). Clusters with a significant
reduction in grey matter density are shown superimposed on a MRI
template (a, c) while clusters with significant glucose hypometabolism
are superimposed on a PET template (b, d). In the bvFTD+ subgroup, the
grey matter density reduction can be seen in the left inferior frontal gyrus
and cingulate gyrus, and in the right insula and claustrum (a), and
hypometabolism is in the bilateral medial frontal gyri, left inferior
frontal gyrus, postcentral gyrus and caudate nucleus, as well as in the
right superior temporal gyrus and insula (b). In the bvFTD− subgroup
(c, d), the grey matter density reduction is in the left superior and right
inferior frontal gyri, left precentral gyrus and left inferior parietal lobule
(c), and hypometabolism is in the left superior and inferior frontal gyri,
bilateral inferior parietal lobule and right precentral gyrus (d). The colour
bars indicate the level of Z scores for significant voxels. Note that the
range of colour bars is 0 – 4 forMRI and 0 – 6 for FDG PET reflecting the
higher level of statistical significance for the latter. See Tables 5 and 6 for
details of Talairach coordinates
1344 Eur J Nucl Med Mol Imaging (2016) 43:1337–1347
hypometabolism was found in the left hippocampus,
parahippocampal gyrus and thalamus, thus reproducing a sim-
ilar finding in AD [30] that has been explained by either the
relatively lower accuracy (i.e. spatial resolution) of FDG PET
as compared with MRI in deep, small structures near the me-
dian line or hypothesizing a metabolic compensation mecha-
nism at those sites [36].
The present group of bvFTD patients was characterized by
a rather late age at onset (mean 71.7 years), the same as that
reported in a recent cohort of patients with late-onset bvFTD
[37]. In a recent, large study with an upward cut-off of
75 years, the patients’ mean age was 62.7 years, thus not so
far from ours if that cut-off had not been used [19]. Indeed,
bvFTD patients older than 65 years are increasingly recog-
nized [38]. Thus our group can be characterized as having
‘late-onset’ bvFTD and the results should not be generalized
to include those with ‘early-onset’ bvFTD. The relatively old
age of the patients at onset could have been a result of the
nature of our centre that is a neurological unit devoted to
dementia of the elderly and of the peculiarities of our geo-
graphic area with a rather high prevalence of elderly people.
A similar phenomenon has been found in patients with de
novo Parkinson’s disease, who show a rather late mean age
at onset of 68 years [39].
Networks underlying different behavioural presentations
As has been shown in patients with overt bvFTD, integration
of behavioural and imaging assessments confirmed that the
disinhibited or apathetic presentations are associated with dif-
ferent sites of both functional [6, 13] and structural [40] dam-
age. Both hypometabolism and atrophy were more evident in
orbitofrontal and temporal brain structures in disinhibited pa-
tients and in the dorsolateral frontal cortex in apathetic pa-
tients. Previous studies have shown that a major variable de-
termining the behavioural manifestations of FTD at onset is
the initial location of the disease [6, 11, 12]. It has been sug-
gested that apathy is associated with more widespread cortical
atrophy, mainly involving the dorsolateral frontal cortex [5].
Our results support this concept for at least two reasons, strict-
ly related to our multimodal imaging approach. First, GM
density reduction was indeed more extensive in the bvFTD−
than in the bvFTD+ subgroup. Second, in the bvFTD− sub-
group, clusters of atrophy and metabolic impairment in the
dorsolateral frontal cortex tended to overlap to a greater extent
than in the bvFTD+ subgroup, suggesting that more extended
atrophy was already present together with hypometabolism at
the first evaluation.
By contrast, in the bvFTD+ subgroup, clusters of
hypometabolism were much more extensive than GM density
reduction involving the inferomedial frontal cortex, caudate
nucleus and superior temporal cortex. Accordingly, these pa-
tients might be at an earlier stage of the disease because their
disinhibited and aggressive behaviour has a higher negative
social impact, and thus they might present for neurological
consultation even earlier than bvFTD− patients. Indeed, both
the NPI and the MMSE scores tended to be higher in the
bvFTD+ subgroup, although not significantly, indicating a
more severe behavioural impact but with milder cognitive
impairment. The bvFTD+ subgroup, characterized by
hypometabolism extending to the temporal lobes, showed sig-
nificantly higher NPI scores for the agitation, irritability and
euphoria items. It has been previously suggested that dysthy-
mia and agitation are particularly associated with right tempo-
ral function [13] that affects, anger, sadness and fear, and may
be responsible for exaggerated reactions to sensory stimuli
[41].
Involvement of the striatum in the bvFTD group with
socially inappropriate behaviours may be expected as the stri-
atum plays a key role in the system responsible for reinforce-
ment and reward, as well as for goal-directed behaviours [42].
Similarly lack of significant involvement of the basal ganglia
in the apathetic subgroup is in keeping with the hypothesis
that the aetiology of apathy seen in bvFTD patients differs
from that in patients with damage to the basal ganglia possibly
reflecting the direct involvement of the prefrontal cortex that
may contribute to loss of motivation [43]. Finally, the more
prominent structural and functional damage in the insula in the
bvFTD+ subgroup might reflect its role in self-awareness and
emotions. The insula is involved in decision-making process-
es by integrating information about the internal emotional/
arousal states and the risk or uncertainty associated with cur-
rent decisions [44].
The main strengths of this study are the availability of both
morphological and functional data in the same patients, both
collected during the predementia stage of bvFTD. The main
limitations are the limited number of patients in each bvFTD
subgroup, the availability of only the most frequent genetic
markers, and the lack of histopathological confirmation.
Another potential limitation is that we did not use the FTLD
−modified CDR [45] to generate a ‘global’ rating, although a
retrospective evaluation of the added ‘language’ domain led to
a score of 0 or 0.5, while the other domain ‘behaviour’ could
not be retrospectively evaluated. This choice might have in-
fluenced patient selection to some extent.
In conclusion, both hypometabolism and GM density re-
duction can be found in the predementia stage of bvFTD, with
some overlap. However, hypometabolism is far more exten-
sive and with more highly significant differences than GM
atrophy as compared with controls. Combined structural and
functional analysis of behavioural profiles allowed early
frontolimbic and frontoparietal functional network damage
to be identified in bvFTD patients. The findings related to
patients’ behavioural profiles confirm that the disinhibited
and apathetic presentations are mainly associated with differ-
ent functional patterns. These findings support the use of
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neuroimaging, especially FDG PET, to reveal functional fail-
ure in predementia bvFTD patients to support the clinical di-
agnosis during this early stage. This may have implications for
therapeutic clinical trials to exclude patients with more benign
phenocopies.
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